|Agreement labeling||EMERALD CONSORTIUM SALES AGREEMENT|
|Has the agreement been fully disclosed and published?||No|
|Agreement period||08/04/2022 – 12/31/2024|
|Consortia / Institution||b-on / FCT|
Approximate range of annual corresponding author publications
|Comments on size/article output||30 (in 9 subscribing institutions)|
How do the costs of the agreement relate to previous subscription-only agreements with the publisher?
|Agreement costs within the range of the previous spending level|
Transfomative agreements vary by their transformative mechanisms, meaning the way in which financing is shifted from the subscription side to open access publishing. What are the characteristics of this agreement to this regard?
|Subscriptions partly converted to OA publishing fees|
How do entitlements for open access publishing correlate to the anticipated article output? Which mechanisms for risk sharing have been agreed in cases of exceeding or not reaching the number of OA publishing entitlements?
|Capped agreement. Expected output only partially covered.|
Are all journals relevant to your affiliated authors (in which you expect them to publish) eligible for OA publishing under the agreement?
|Are fully open access journals covered by the agreement?||Yes|
|OA LICENSE||CC-BY preference, exceptions allowed|
||Original research articles
Other peer-reviewed article types
What is the approximate share of access related costs of the overall agreement?
|Comments on access costs||Difficult to assess|
Are all read relevant journals covered by the agreement?
|PERPETUAL ACCESS RIGHTS||Yes|
|Request contact to the licensee||contact [at] esac-initiative [dot] org|